Last Update 03 May 26
Recursion Pharmaceuticals (RXRX) one day will be the Palantir of biotechnology! With the CMO transitioning out as well as the former CEO RXRX now has a chance to take off! Vikki Goodman and Najat Khan can now lead RXRX back to respectability and acceptance as a real leader in biotechnology! Once the announcements start coming in on REC-4881 going to Phase 3 and beyond this stock will skyrocket! RXRX finally has the right people in place to do their jobs correctly! Many institutions will soon be coming in with more good news to follow!!!
RXRX is a terrible biotech only because the INSIDERS themselves don’t believe in it! All they’re doing is milking the heck out of this doomed stock! Never seen a company where ALL they’re doing insiders are selling! Stock continues to go down every month! CEO said in 2014 that in 10 years there would be 100 new drugs! 12 years later they have ZERO 0️⃣!!! This stock went from over $40 to under $4! The hype is unbelievable! Worst biotech ever!!! Nuff said
Have other thoughts on Recursion Pharmaceuticals?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Comments
0 commentsDisclaimer
The user 537578 holds no position in NasdaqGS:RXRX. Simply Wall St has no position in any of the companies mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The author of this narrative is not affiliated with, nor authorised by Simply Wall St as a sub-authorised representative. This narrative is general in nature and explores scenarios and estimates created by the author. The narrative does not reflect the opinions of Simply Wall St, and the views expressed are the opinion of the author alone, acting on their own behalf. These scenarios are not indicative of the company's future performance and are exploratory in the ideas they cover. The fair value estimates are estimations only, and does not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that the author's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Read more narratives
High R&D Burn And Regulatory Hurdles Will Cripple Future Value
View narrative
OS 20 Will Accelerate AI Drug Discovery And Clinical Milestones
View narrative
Moving from "Science Fiction" to "Science Fact" – A Bullish Valuation Case
View narrative
Advanced AI And ML Will Transform Biotech Drug Discovery
View narrative